HKU Scholars Hub: Browsing DSpace

Browsing by Author Flaherty, JF

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 9 of 9

	Title	Author(s)	Issue Date	Views
	Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV Journal:PLoS One	Pan, CQ Chang, TT Bae, SH Brunetto, M Seto, WK Coffin, CS Tan, SK Mo, S Flaherty, JF Gaggar, A Nguyen, MH Celen, MK Thompson, A Gane, EJ Bulterys, M	2021	12
	Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks Journal:Alimentary Pharmacology and Therapeutics	Fung, SK Pan, CQ Wong, GL Seto, WK Ahn, SH Chen, CY Hann, HL Jablkowski, MS Kim, YJ Yurdaydin, C Peng, CY Nguyen, T Yatsuhashi, H Flaherty, JF Yee, LJ Abramov, F Wang, H Abdurakhmanov, D Lim, YS Buti, M	31-Oct-2023
	Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year after Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) Proceeding/Conference:Hepatology	Seto, WKW Buti, M Izumi, N Lim, YS Kao, JH Streinu-Cercel, A Nurmukhametova, E Ma, X Tabak, F Jablkowski, M Suri, V Flaherty, JF Lau, AH Gaggar, A Mo, S Chowdhury, A Fung, SK Chuang, WL Gane, EJ	2018	73
	IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) Proceeding/Conference:Hepatology	Lim, Y Chan, HLY Seto, WKW Ning, Q Agarwal, K Janssen, HL Pan, CQ Chuang, WL Izumi, N Fung, SK Shalimar,Brunetto, MR Flaherty, JF Mo, S Cheng, C Lin, L Gaggar, A Subramanian, M Marcellin, P Gane, EJ Hou, J Buti, M	2019	120
	RETRACTION: Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection Journal:Clinical Gastroenterology and Hepatology	Seto, WKW Asahina, Y Brown, TT Peng, CY Stanciu, C Abdurakhmanov, D Tabak, F Nguyen, TT Chuang, WL Inokuma, T Ikeda, F Santantonio, TA Habersetzer, F Ramji, A Lau, AH Suri, V Flaherty, JF Wang, H Gaggar, A Subramanian, GM Mukewar, S Brunetto, MR Fung, S Chan, HL	2018	50
	Review: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data Journal:Alimentary Pharmacology & Therapeutics	Lim, YS Seto, WKW Kurosaki, M Fung, S Kao, JH Hou, J Gordon, SC Flaherty, JF Yee, LJ Zhao, Y Agarwal, K Lampertico, P	2022	9
	Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use Proceeding/Conference:Journal of Hepatology	Gane, E Seto, WKW Janssen, H Carantu, FA Kim, HJ Abdurakhmanov, D Nishiguchi, S Andrzej, H Bae, H Mo, S Suri, V Gaggar, A Flaherty, JF Kao, JH Brunetto, M Ferret, MB	2018	101
	Tenofovir alafenamide (TAF) compared with Tenofovir Dispoproxil Fumarate (TDF) in patients with chronic HBV: week 96 efficacy and safety results in Chinese patients enrolled in 2 overseas phase 3 studies Proceeding/Conference:Chinese Infectious Disease and Hepatology Conference	Seto, WKW Fung, S Hou, J Pan, C Chuang, WL Chang, TT Hui, AJ Chen, CY Ma, X Tam, E Tsang, TY Yang, J Flaherty, JF Gaggar, A Mo, S Tong, M Kao, JH Chan, HL	2017	123
	Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B Proceeding/Conference:Hepatology	Chan, HLY Lim, YS Seto, WKW Agarwal, K Brunetto, MR Janssen, HLA Caruntu, F Stepanova, T Tsang, O Yatsuhashi, H Tak, WY Chen, CY Celen, M Sun, V Flaherty, JF Lin, L Cathcart, A Gaggar, A Pan, CQ Shalimar Buti, M	2018	384

Showing results 1 to 9 of 9